These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1094 related articles for article (PubMed ID: 32200389)

  • 21. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
    Seyhan AA
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.
    Nordgård O; Tjensvoll K; Gilje B; Søreide K
    Br J Surg; 2018 Jan; 105(2):e110-e120. PubMed ID: 29341153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Introduction and Clinical Application of Cell-Free Tumor DNA.
    Li J; Liu R; Huang C; Chen S; Xu M
    Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
    Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
    Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liquid biopsy: novel technologies and clinical applications.
    Reimers N; Pantel K
    Clin Chem Lab Med; 2019 Feb; 57(3):312-316. PubMed ID: 30465714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunities of circulating tumor DNA in lung cancer.
    Wu TH; Hsiue EH; Yang JC
    Cancer Treat Rev; 2019 Aug; 78():31-41. PubMed ID: 31326635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
    Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
    J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating-tumor DNA as an early detection and diagnostic tool.
    Butler TM; Spellman PT; Gray J
    Curr Opin Genet Dev; 2017 Feb; 42():14-21. PubMed ID: 28126649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
    Nakamura K
    Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.